ST龙宇、ST华微陷财务困局，广济药业、祥源文旅被证监会盯上

Core Viewpoint - The article highlights the increasing regulatory scrutiny in the capital market, emphasizing a "zero tolerance" approach towards financial fraud, information disclosure violations, and fund misappropriation by listed companies. Group 1: ST Longyu - ST Longyu has been placed under investigation by the China Securities Regulatory Commission (CSRC) for suspected information disclosure violations, with a total of 8.7 billion yuan in fund misappropriation involved [1][2] - The company’s controlling shareholder and related parties have non-operational fund misappropriation totaling 9.18 billion yuan, of which 8.68 billion yuan remains unpaid [2] - The audit report for ST Longyu's 2023 annual report was issued with a "disclaimer of opinion," leading to increased delisting risks for the company [2] Group 2: ST Huamei - ST Huamei has been formally investigated by the CSRC for suspected information disclosure violations, with a self-reported non-operational fund misappropriation of 14.35 billion yuan [3][4] - The company reported significant fund flows lacking real commercial substance, with total outflows of 81.39 billion yuan and inflows of 68.52 billion yuan [3] - The ongoing investigation will impact the company's compliance risks and market reputation [3] Group 3: Guangji Pharmaceutical - Guangji Pharmaceutical has received a notice from the CSRC regarding an investigation for suspected information disclosure violations, following a previous warning from the Hubei Securities Regulatory Bureau [4][5] - The company acknowledged accounting errors in its financial reports, leading to adjustments in previously reported revenue and costs [4] - The CSRC's investigation marks an escalation in regulatory scrutiny regarding the company's compliance with information disclosure requirements [5] Group 4: Xiangyuan Cultural Tourism - Xiangyuan Cultural Tourism and its actual controller have been placed under investigation by the CSRC for suspected information disclosure violations [5] - The specific details of the violations have not yet been disclosed, but the investigation will assess the company's compliance with securities laws [5] - The outcome of the investigation is expected to be a focal point for market participants [5]